1. Home
  2. CALC vs PMN Comparison

CALC vs PMN Comparison

Compare CALC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • PMN
  • Stock Information
  • Founded
  • CALC 2011
  • PMN 2004
  • Country
  • CALC United States
  • PMN Canada
  • Employees
  • CALC N/A
  • PMN N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • CALC Health Care
  • PMN Health Care
  • Exchange
  • CALC Nasdaq
  • PMN Nasdaq
  • Market Cap
  • CALC 36.0M
  • PMN 29.8M
  • IPO Year
  • CALC N/A
  • PMN N/A
  • Fundamental
  • Price
  • CALC $2.61
  • PMN $0.96
  • Analyst Decision
  • CALC Strong Buy
  • PMN
  • Analyst Count
  • CALC 5
  • PMN 0
  • Target Price
  • CALC $18.20
  • PMN N/A
  • AVG Volume (30 Days)
  • CALC 31.0K
  • PMN 43.3K
  • Earning Date
  • CALC 03-27-2025
  • PMN 03-31-2025
  • Dividend Yield
  • CALC N/A
  • PMN N/A
  • EPS Growth
  • CALC N/A
  • PMN N/A
  • EPS
  • CALC N/A
  • PMN N/A
  • Revenue
  • CALC N/A
  • PMN N/A
  • Revenue This Year
  • CALC N/A
  • PMN N/A
  • Revenue Next Year
  • CALC N/A
  • PMN N/A
  • P/E Ratio
  • CALC N/A
  • PMN N/A
  • Revenue Growth
  • CALC N/A
  • PMN N/A
  • 52 Week Low
  • CALC $2.05
  • PMN $0.87
  • 52 Week High
  • CALC $6.27
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • CALC 43.94
  • PMN 56.16
  • Support Level
  • CALC $2.32
  • PMN $0.90
  • Resistance Level
  • CALC $3.05
  • PMN $0.95
  • Average True Range (ATR)
  • CALC 0.27
  • PMN 0.06
  • MACD
  • CALC -0.01
  • PMN 0.01
  • Stochastic Oscillator
  • CALC 43.29
  • PMN 67.79

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: